These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 14725034)

  • 1. [Physical activity in hyperglycemia and type 2 diabetes. Effective but still underutilized].
    Zimmer P
    MMW Fortschr Med; 2003 Nov; 145(47):49-52. PubMed ID: 14725034
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
    Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
    J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet needs in controlling metabolic disease.
    Haffner SM
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical aspects of physical exercise for diabetes/metabolic syndrome.
    Sato Y; Nagasaki M; Kubota M; Uno T; Nakai N
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S87-91. PubMed ID: 17498834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome.
    Kraemer de Aguiar LG; Laflor CM; Bahia L; Villela NR; Wiernsperger N; Bottino DA; Bouskela E
    Diabet Med; 2007 Mar; 24(3):272-9. PubMed ID: 17263761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
    Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
    Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention by life style intervention and medication. To run away from type 2 diabetes].
    Wepner U
    MMW Fortschr Med; 2004 Apr; 146(14):16. PubMed ID: 15344745
    [No Abstract]   [Full Text] [Related]  

  • 8. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
    de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
    Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of type 2 diabetes in the prediabetic population.
    Maji D; Roy RU; Das S
    J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin for the treatment of the polycystic ovary syndrome.
    Barbieri RL; Gargiulo AR
    Minerva Ginecol; 2004 Feb; 56(1):63-79. PubMed ID: 14973411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.
    Lorenzo C; Williams K; Hunt KJ; Haffner SM
    Diabetes Care; 2007 Jan; 30(1):8-13. PubMed ID: 17192325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
    Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
    Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired glucose tolerance and impaired fasting glucose.
    Rao SS; Disraeli P; McGregor T
    Am Fam Physician; 2004 Apr; 69(8):1961-8. PubMed ID: 15117017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's preventing us from preventing type 2 diabetes?
    Fradkin JE; Roberts BT; Rodgers GP
    N Engl J Med; 2012 Sep; 367(13):1177-9. PubMed ID: 23013070
    [No Abstract]   [Full Text] [Related]  

  • 17. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome.
    Casulari LA; Caldas AD; Domingues Casulari Motta L; Lofrano-Porto A
    Minerva Endocrinol; 2010 Sep; 35(3):145-51. PubMed ID: 20938417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome: are we at risk?
    Paudel B
    Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to prevent type 2 diabetes.
    Abuissa H; Bel DS; O'keefe JH
    Curr Med Res Opin; 2005 Jul; 21(7):1107-14. PubMed ID: 16004680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.